Boston Scientific (BSX) closed at $95.41 in the latest trading session, marking a -1.92% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 2.71% for the day.

Read here for Boston Scientific (BSX) stock's outlook ahead of Q3 earnings, assess valuation, margin pressures, and ...

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income ...

Boston Scientific Corp. has announced it has received FDA approval and market launch of its Epic vascular self-expanding stent system, according to a news release. Boston Scientific said the Epic ...

Across the recent three months, 12 analysts have shared their insights on Boston Scientific (NYSE: BSX), expressing a variety ...

MARLBOROUGH, Mass., May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May. On May 13, 2025, Dan Brennan, executive vice ...

The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following ...

Marlborough, Mass.-based Boston Scientific has launched Endura Weight Loss Solutions, a new category name for its minimally invasive endobariatric procedures such as endoscopic sleeve gastroplasty and ...

The FDA has issued an alert about a potentially high-risk issue involving models of Boston Scientific’s Watchman Access Systems, which are used to provide vascular and transseptal access during ...